EP2099457A4 - CYTOSCELETACTIVE RHO-KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE - Google Patents

CYTOSCELETACTIVE RHO-KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE

Info

Publication number
EP2099457A4
EP2099457A4 EP07869450A EP07869450A EP2099457A4 EP 2099457 A4 EP2099457 A4 EP 2099457A4 EP 07869450 A EP07869450 A EP 07869450A EP 07869450 A EP07869450 A EP 07869450A EP 2099457 A4 EP2099457 A4 EP 2099457A4
Authority
EP
European Patent Office
Prior art keywords
cytosquelettic
active
composition
kinase inhibitor
inhibitor compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07869450A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2099457A2 (en
Inventor
John W Lampe
Paul S Watson
David J Slade
Ward M Peterson
Christopher S Crean
Jason L Vittitow
Jonathan Bryan Decamp
Nicholas F Pelz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of EP2099457A2 publication Critical patent/EP2099457A2/en
Publication of EP2099457A4 publication Critical patent/EP2099457A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP07869450A 2006-12-18 2007-12-18 CYTOSCELETACTIVE RHO-KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE Withdrawn EP2099457A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87055506P 2006-12-18 2006-12-18
US11/958,214 US8071779B2 (en) 2006-12-18 2007-12-17 Cytoskeletal active rho kinase inhibitor compounds, composition and use
PCT/US2007/087973 WO2008077057A2 (en) 2006-12-18 2007-12-18 Cytoskeletal active rho kinase inhibitor compounds, composition and use

Publications (2)

Publication Number Publication Date
EP2099457A2 EP2099457A2 (en) 2009-09-16
EP2099457A4 true EP2099457A4 (en) 2011-08-17

Family

ID=39537056

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07869450A Withdrawn EP2099457A4 (en) 2006-12-18 2007-12-18 CYTOSCELETACTIVE RHO-KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE

Country Status (11)

Country Link
US (3) US8071779B2 (OSRAM)
EP (1) EP2099457A4 (OSRAM)
JP (1) JP5511385B2 (OSRAM)
KR (1) KR20090091767A (OSRAM)
CN (2) CN103254172A (OSRAM)
AU (1) AU2007333715B2 (OSRAM)
BR (1) BRPI0720457A2 (OSRAM)
CA (1) CA2672825A1 (OSRAM)
MX (1) MX2009006493A (OSRAM)
RU (1) RU2470928C2 (OSRAM)
WO (1) WO2008077057A2 (OSRAM)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
SI1919290T1 (sl) * 2005-07-12 2014-05-30 Ampio Pharmaceuticals, Inc. Postopki in proizvodi za zdravljenje bolezni
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
JP5592265B2 (ja) 2007-11-01 2014-09-17 アキュセラ インコーポレイテッド 眼の疾患及び障害治療用のアミン誘導体化合物
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
AU2009260628A1 (en) * 2008-06-18 2009-12-23 Inspire Pharmaceuticals, Inc. Process for the preparation of Rho-kinase inhibitor compounds
US20090325960A1 (en) * 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
US8207195B2 (en) * 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20100008968A1 (en) * 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
WO2009158587A1 (en) * 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
US8410147B2 (en) * 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010065782A1 (en) * 2008-12-04 2010-06-10 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
DK2554171T3 (da) * 2009-06-22 2014-11-17 Ampio Pharmaceuticals Inc Fremgangsmåde til behandling af sygdomme
SG177302A1 (en) * 2009-06-22 2012-02-28 Dmi Acquisition Corp Methods and products for treatment of diseases
AU2015203100B2 (en) * 2009-06-22 2017-03-16 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
JP2013513664A (ja) * 2009-12-14 2013-04-22 インスパイアー ファーマシューティカルズ，インコーポレイティド 架橋二環式ｒｈｏキナーゼ阻害化合物、組成および使用
WO2012012282A1 (en) * 2010-07-19 2012-01-26 Inspire Pharmaceuticals, Inc. Bifunctional rho kinase inhibitor compounds, composition and use
WO2012015760A1 (en) * 2010-07-27 2012-02-02 Inspire Pharmaceuticals, Inc. Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
GB201107223D0 (en) * 2011-04-29 2011-06-15 Amakem Nv Novel rock inhibitors
CA2858173C (en) * 2011-12-06 2023-09-26 Advanced Cell Technology, Inc. Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
EA026368B1 (ru) 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
US20130168825A1 (en) * 2011-12-30 2013-07-04 Alliance For Sustainable Energy, Llc Fabrication of ionic liquid electrodeposited cu-sn-zn-s-se thin films and method of making
AU2013307337B2 (en) 2012-08-28 2018-07-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
EA026629B1 (ru) * 2012-10-31 2017-04-28 пиЭйч ФАРМА Ко., ЛТД. Ингибиторы rock
BR112015014261A8 (pt) 2012-12-19 2019-10-08 Ampio Pharmaceuticals Inc composto de danazol, seu uso e formulação farmacêutica compreendendo este
CN105189453B (zh) 2013-02-28 2018-04-10 爱尔兰詹森科学公司 氨磺酰基‑芳基酰胺及其作为用于乙型肝炎治疗的药物的用途
PT3811943T (pt) 2013-03-15 2023-03-15 Aerie Pharmaceuticals Inc Composto para uso no tratamento de distúrbios oculares
WO2014161888A1 (en) 2013-04-03 2014-10-09 Janssen R&D Ireland N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
BR112015028538A2 (pt) 2013-05-17 2017-07-25 Janssen Sciences Ireland Uc derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b
CA2935719C (en) 2013-07-25 2021-11-02 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AU2014338947B2 (en) 2013-10-23 2018-02-22 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
JP6495929B2 (ja) 2014-02-06 2019-04-03 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイルピロールアミド誘導体およびｂ型肝炎の治療のための医薬としてのその使用
US10335449B2 (en) 2014-10-06 2019-07-02 University Of Houston System Rho associated kinase (ROCK) inhibitors and their use in treating disease
AU2016232801A1 (en) 2015-03-19 2017-10-12 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
JP6883173B2 (ja) 2015-05-12 2021-06-09 ヘモストッド エスエー 改善された血小板産生のための薬理学的特徴およびマイクロ流体特徴の組み合わせ
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
WO2017086941A1 (en) 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
EP3585790A1 (en) * 2017-02-27 2020-01-01 Janssen Pharmaceutica NV [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
BR112020008850A2 (pt) * 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
MA52019A (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
CN108929258A (zh) * 2018-07-09 2018-12-04 张立国 一种Rho激酶抑制剂及其在癌症治疗中的应用
CN108569990A (zh) * 2018-07-09 2018-09-25 张立国 多取代吡咯烷衍生物及其作为Rho激酶抑制剂在癌症中的应用
CN119080779A (zh) 2018-08-10 2024-12-06 阿克拉瑞斯治疗股份有限公司 吡咯并嘧啶itk抑制剂
WO2020047229A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US12048678B2 (en) 2018-10-02 2024-07-30 Case Western Reserve University Compounds for treating myelin related disorders
CA3127152A1 (en) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CN110215519A (zh) * 2019-07-12 2019-09-10 温州医科大学附属眼视光医院 药物修饰型人工晶状体及其制备方法和应用
CN114133394B (zh) * 2020-08-12 2023-12-08 赛诺哈勃药业（成都）有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途
MX2024002173A (es) 2021-08-18 2024-03-26 Chemocentryx Inc Compuestos de arilsulfonilo como inhibidores de ccr6.
KR20240049280A (ko) 2021-08-18 2024-04-16 케모센트릭스, 인크. Ccr6 억제제로서의 아릴 설포닐(하이드록시) 피페리딘
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN116891460A (zh) * 2023-07-12 2023-10-17 浙江大学 一种吲唑类衍生物或其药用盐及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1256574A1 (en) * 2000-02-01 2002-11-13 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
EP1403255A1 (en) * 2001-06-12 2004-03-31 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
WO2006135383A2 (en) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524816A (en) * 1984-02-21 1985-06-25 Dentsply Research & Development Corp. Centrifugal casting furnace
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
CN101310771B (zh) 2001-04-11 2012-08-08 千寿制药株式会社 视觉功能障碍改善剂
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
US6867221B2 (en) 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
ES2382733T3 (es) 2002-08-29 2012-06-13 Santen Pharmaceutical Co., Ltd. Remedio para el glaucoma que comprende un inhibidor de la Rho quinasa y prostaglandinas
CA2502583A1 (en) * 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same
WO2005019190A2 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
JP2008519814A (ja) * 2004-11-12 2008-06-12 ガラパゴス・ナムローゼ・フェンノートシャップ プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
RU2435769C2 (ru) * 2005-05-20 2011-12-10 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиридины, полезные в качестве ингибиторов протеинкиназы
KR20080026654A (ko) * 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1256574A1 (en) * 2000-02-01 2002-11-13 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
EP1403255A1 (en) * 2001-06-12 2004-03-31 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
WO2006135383A2 (en) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles

Also Published As

Publication number Publication date
EP2099457A2 (en) 2009-09-16
BRPI0720457A2 (pt) 2014-01-14
US8071779B2 (en) 2011-12-06
JP5511385B2 (ja) 2014-06-04
US20130012543A1 (en) 2013-01-10
RU2470928C2 (ru) 2012-12-27
CA2672825A1 (en) 2008-06-26
US20120046275A1 (en) 2012-02-23
US8604218B2 (en) 2013-12-10
CN103254172A (zh) 2013-08-21
AU2007333715A1 (en) 2008-06-26
CN101583361A (zh) 2009-11-18
CN101583361B (zh) 2013-01-23
MX2009006493A (es) 2009-09-10
AU2007333715B2 (en) 2013-01-10
WO2008077057A2 (en) 2008-06-26
WO2008077057A3 (en) 2008-08-21
KR20090091767A (ko) 2009-08-28
RU2009127798A (ru) 2011-01-27
US20080214614A1 (en) 2008-09-04
JP2010513319A (ja) 2010-04-30
US8604205B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
EP2099457A4 (en) CYTOSCELETACTIVE RHO-KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
EP1951684A4 (en) BIARYLMETAPYRIMIDINKINASEINHIBITOREN
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
EP1807077A4 (en) INHIBITORS OF C-FMS KINASE
DK2021335T3 (da) Heterocykliske forbindelser som C-FMS-kinasehæmmere
EP2143443A4 (en) COMBINED USE OF A DIPEPTIDYL PEPTIDASE IV INHIBITOR COMPOUND AND A SWEETENER
EP2120578A4 (en) KINASE INHIBITORS COMPOUNDS
EP2079727A4 (en) KINASE INHIBITOR COMPOUNDS
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
ATE512972T1 (de) Pyrrolopyrazole als wirksame kinaseinhibitoren
SMP200900058B (it) Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it) Composti e composizioni come inibitori di proteinachinasi.
NO20082517L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
BRPI0906973A2 (pt) Compostos e composições como inibidores de cinase.
DK2848610T3 (da) Hæmmere af kinaseaktivitet
BRPI0820544A2 (pt) 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0719797A2 (pt) compostos e composições como inibidores de proteína cinase
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
EP2044055A4 (en) amide compounds
BRPI0815979A2 (pt) compostos e composições com inibidores de quinase, bem como uso dos mesmos
DK1928879T3 (da) Kondenserede heterocykliske forbindelser og anvendelse heraf som kinase-modulatorer
MA28822B1 (fr) Benzamides substitues trifluoromethyle comme inhibiteurs de kinase
EP2376425A4 (en) KINASE INHIBITORS COMPOUNDS
BRPI0716781A2 (pt) Inibidores da quinase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090715

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PETERSON, WARD M.

Inventor name: VITTITOW, JASON L.

Inventor name: CREAN, CHRISTOPHER S.

Inventor name: WATSON, PAUL S.

Inventor name: SLADE, DAVID J.

Inventor name: PELZ, NICHOLAS F.

Inventor name: DECAMP, JONATHAN BRYAN

Inventor name: LAMPE, JOHN W.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110720

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/47 20060101ALI20110714BHEP

Ipc: A61K 31/505 20060101AFI20110714BHEP

17Q First examination report despatched

Effective date: 20120803

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160707